Questions discussed in this category
ESOPEC compared perioperative FLOT vs neoadjuvant chemoradiation per the CROSS trial, and showed superior OS with perioperative FLOT. What concerns do...
Given that LU002 has failed to meet its progression free survival benefit in results presented at ASCO, will you offer consolidative radiotherapy for ...
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical prac...
Papers discussed in this category
N Engl J Med,
The Lancet. Oncology, 2023 Sep 12
N Engl J Med, 2019 02 28